Podcasts about Harvard Medical School

When we think about gene editing, the conversation often feels trapped between scientific journals and ethical debates too complex for public forums. In this episode, I spoke with Neal Baer, a rare voice who bridges both worlds. Known to many as an award-winning television showrunner for series like ER, Law & Order SVU, and Designated Survivor, Neal is also a Harvard-trained physician and co-director of the Media, Medicine, and Health program at Harvard Medical School. His latest project brings all of that experience together in a new collection of essays that explores the promise and peril of CRISPR gene-editing technology. Neal takes us on a journey that begins with his time as a medical resident treating a young sickle cell patient, and leads to a much broader conversation about science, ethics, and storytelling. We discuss how CRISPR is already being used to cure diseases like sickle cell, and how companies are now exploring gene edits that promise permanent reductions in cholesterol. But the real power of this discussion is not just in what CRISPR can do, but in what we still don't fully understand about its long-term impact. The conversation moves into difficult territory—unintended mutations, germline editing, the risk of pathologizing human diversity, and the slippery slope of “enhancement” where only those with access can benefit. Neal raises critical questions about the social cost of deciding which conditions should be “fixed” and who gets to make that call. We also dive into the lack of political and regulatory oversight, and why a global framework, not just scientific advancement, is urgently needed. This episode offers a powerful reminder that the future of CRISPR shouldn't be left solely to researchers or startups. It demands wide engagement, from classrooms to policymaking, and inclusive voices that challenge how we define progress. How should we decide what counts as improvement when the very definition of being human is at stake?

What are some practical ways to make an impact as a leader? In this episode, Kevin welcomes Margaret Moore and Jeffrey Hull to discuss how leaders can close the gap between science and real-world application. Margaret and Jeffrey translated hundreds of leadership studies into nine capacities. These are grouped into three levels: self, relationships with others, and the larger organizational and societal impact. They share what it means to lead intentionally, develop agility and authenticity, and build psychologically safe environments. They also talk about concepts like the "quiet ego," balancing compassion and strategy, and why conscious leadership underpins all other capacities. Listen For 0:00 Introduction and Framing the Conversation 1:16 About the Podcast and Live Opportunities 1:48 Kevin Introduces His Book Flexible Leadership 2:15 Guest Introductions Margaret Moore and Jeffrey Hull 3:14 Why the Word “Impact” 5:26 How the Book Came to Be 8:09 Researching the Research 13:28 Three Segments of Leadership Capacities 17:32 The 3 Self Focused Capacities 19:39 The 3 Team or Other Focused Capacities 23:39 The 3 Organization Focused Capacities 27:48 Most Misunderstood Capacities 30:12 The Concept of the Quiet Ego 32:42 Book Takeaways and Closing Reflections 35:03 What They're Reading 37:04 Where to Learn More 38:24 Kevin's Final Challenge Now What Their Story: Jeffrey Hull, PhD, and Margaret Moore, MBA are the authors of The Science of Leadership: Nine Ways to Expand Your Impact. Jeffery has focused on leadership for over 30 years, as an HR leader with multiple corporations, cofounder of a leadership development consultancy, nonprofit executive director, and coach to leaders across the globe. He brings years of translating science into leadership as a consultant, psychologist, and teacher at New York University and Harvard Medical School. In writing this book, Jeff is excited to see his chosen professions—leadership and coaching—getting the scientific attention and application they deserve. Margaret blends leadership, coaching, and science, including thirty years in C-suite roles, co-leading four successful start-ups in biotechnology and coaching, and two decades of professional coaching and coach training. For 25 years, she has been a prolific translator of science into coaching, training, and leadership practice. Margaret's vision for this book is to help bring scientists, leaders, and coaches together to foster leadership excellence and support everyday leaders far and wide. https://www.scienceofleadership.com/ https://www.linkedin.com/in/jeffreywhull/ https://www.linkedin.com/in/coachmeg/ This Episode is brought to you by... Flexible Leadership is every leader's guide to greater success in a world of increasing complexity and chaos.  Book Recommendations The Science of Leadership: Nine Ways to Expand Your Impact by Jeffrey Hull and Margaret Moore  The Transformative Self: Personal Growth, Narrative Identity, and the Good Life (Explorations in Narrative Psychology) by Jack J. Bauer  The Trauma of Everyday Life by Mark Epstein M.D Thoughts Without A Thinker: Psychotherapy from a Buddhist Perspective by Mark Epstein Rise Above: Overcome a Victim Mindset, Empower Yourself, and Realize Your Full Potential by Scott Barry Kaufman PhD James by Percival Everett Like this? Cracking the Leadership Code with Alain Hunkins Connecting with Others Through Listening with Ximena Vengoechea Join Our Community If you want to view our live podcast episodes, hear about new releases, or chat with others who enjoy this podcast join one of our communities below. Join the Facebook Group Join the LinkedIn Group   Leave a Review If you liked this conversation, we'd be thrilled if you'd let others know by leaving a review on Apple Podcasts. Here's a quick guide for posting a review. Review on Apple: https://remarkablepodcast.com/itunes    Podcast Better! Sign up with Libsyn and get up to 2 months free! Use promo code: RLP  

Recorded in November, 2024, Meg welcomes Dr. Monica Soni, Chief Medical Officer of Covered California, a free service that connects Californians with brand name health insurance under the Affordable Care Act. Dr. Monica Soni is the Chief Medical Officer of Covered California and a practicing primary care physician. She is a board member at Mercy Housing California and previously served on the Los Angeles County Hospital and Healthcare Delivery Commission. Dr. Soni holds a medical degree from Harvard Medical School and is deeply committed to improving population health, reducing disparities, and ensuring healthcare is accessible and affordable for all.In this episode of Game-Changing Women of Healthcare, Monica speaks about driving meaningful healthcare reform from within one of the country's largest health insurance marketplaces. With nearly 1.8 million Californians enrolled, Covered California is tackling some of the system's toughest challenges: provider shortages, cost barriers, health plan accountability, and fragmented care. Dr. Soni opens up about launching statewide initiatives that link financial incentives to quality improvement, reducing deductibles for enrollees, and holding health plans to a higher standard.A practicing primary care physician and former commissioner for the Los Angeles County Hospital and Healthcare Delivery Commission, Dr. Soni brings a unique, on-the-ground perspective to policy leadership. This is a must-listen for anyone passionate about the future of equitable, high-quality, and sustainable care.Further Reading: -Dr. Monica Soni's LinkedIn: https://www.linkedin.com/in/drmonicasoni/-Covered California: www.coveredca.com-Mercy Housing California: https://www.mercyhousing.org/california/-The California Kids Investment and Development Savings Program (CalKIDS): https://calkids.org/about/-California Child Savings Account Program: https://www.capta.org/child-savings-account-UCLA: https://www.ucla.edu/-Charles R. Drew University of Medicine and Science: https://www.cdrewu.edu/Episode Credits: The Game-Changing Women of Healthcare is a production of The Krinsky Company. Hosted by Meg Escobosa. Produced by Meg Escobosa, Calvin Marty, Chelsea Ho, and Wendy Nielsen.Edited, engineered, and mixed by Calvin Marty. All music composed and performed by Calvin Marty. ©2025 The Krinsky Company

Pregnancy with type 1 diabetes requires tight management—but what if the very tools designed to help aren't designed or approved for pregnancy? We're talking about the T1D Pregnancy & Me study, a groundbreaking effort to close the data gap and include pregnant women in diabetes tech research. We'll go through who can be in this study, how It works, what they're looking for and what it could mean for the future of diabetes care during those nine months and a lot more. My guests are: Dr Camille E. Powe, an Associate Professor at Massachusetts General Hospital and Harvard Medical School and the study's Chair and Carrie Matuzsan, a patient advisor. Carrie lives with type 1 and had twins in 2020. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about the study here Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Are we closer to overcoming Alzheimer's disease than most people think?Harvard-trained physician Dr. Joshua Helman exposes how dementia and Alzheimer's stem from multiple interconnected triggers: environmental toxins, chronic stress, inflammation, infections, poor sleep, and even thyroid imbalances.Today, cognitive symptoms are appearing in younger populations at unprecedented rates. Dr. Helman explains how cutting-edge brain imaging and comprehensive functional testing can identify the true mechanisms driving memory loss.You'll also hear about practical, science-backed strategies that can halt or even reverse cognitive decline.Listen now and know that there's hope for you or loved ones suffering from Alzheimer's.Episode Timeline: 00:00 – Episode Overview01:12 – Podcast Intro01:46 – Meet Dr. Joshua Helman03:24 – Why He Focuses on Alzheimer's04:54 – Dementia vs. Alzheimer's06:21 – Can Alzheimer's Be Reversed?07:49 – Deep Sleep: Top Risk Factor08:44 – Early-Onset Alzheimer's in 40s/50s09:25 – How Alzheimer's Is Diagnosed Today10:29 – Thyroid Problems & Brain Health11:37 – Inflammation as an Umbrella Cause13:19 – Brain Damage & Autoimmune Testing14:18 – Diet and Brain Vessel Damage15:11 – Plant-Based Eating & DHA Sources16:57 – Stress as a Major Trigger18:08 – Stress Relief & Social Connection20:26 – Fasting for Brain Health23:48 – Gut Inflammation & Refeeding After Fasting27:24 – Toxins & Plastics in the Brain30:11 – Aluminum, Heavy Metals & Alzheimer's31:32 – Hope for Advanced Cases33:08 – Personalized Treatments & Plasma Exchange34:33 – Functional Testing for Toxins & Infections36:21 – Viruses, Lyme & Dementia Risk38:16 – Multi-Therapy Approach for Alzheimer's39:23 – Oxygen Therapy & BDNF Benefits40:55 – How to Connect with Dr. Helman42:22 – Podcast Outro42:47 –Post-Episode Takeaways About Dr. Joshua Helman:Dr. Joshua Helman, MD is a Harvard-trained physician licensed in 14 states. He holds two degrees in biochemistry, a bachelor's degree (magna cum laude) from Harvard and a master's degree from the University of Cambridge, UK. His medical degree is from Harvard Medical School and MIT. He is board certified by the American Board of Emergency Medicine and the American Board of Lifestyle Medicine. He is the former and current medical director of Hippocrates Health Institute, as well as Chief Medical Officer of 2 different Alzheimer's Reversal Centers: BrainPower Clinics and Alzheimer's Treatment Centers of America. He has worked at the TrueNorth Health Center with a focus on fasting.He recently launched a weekly podcast called Alzheimer's Breakthrough, and his areas of interest span longevity, regeneration, vitality, toxins, mold, Lyme disease, energy medicine and breathwork. With a passion for applying biochemical knowledge to r Do You Want Help Saving Your Thyroid? Click Here to access hundreds of free articles and blog posts. Click Here for Dr. Eric's YouTube channel Click Here to join Dr. Eric's Graves' disease and Hashimoto's group Click Here to take the Thyroid Saving Score Quiz Click Here to get all of Dr. Eric's published booksClick Here to work with Dr. Eric

Dr Akila Viswanathan speaks with Dr Sophia Kamran from Harvard Medical School and Dr Constantinos Zamboglou from the German Oncology Center about the latest edition of Seminars in Radiation Oncology focusing on new treatments for advanced prostate cancer.

In 2004, Madelaine Weiss had a flesh-eating disease, which started as strep throat and extended into her arm. She had a 1% chance of survival. The doctors were threatening to remove her upper right quadrant, but after seven weeks in the hospital and three months off her post at Harvard Medical School, here she is – happy, healthy, prosperous, and productive with a smile. Madelaine Weiss is a Harvard-trained licensed psychotherapist and mindset expert, with an MBA and board certification in executive, career, and life coaching. She is the founder and former chair of The School-Business Partnership, former parenting education facilitator, group mental health practice administrative director, corporate chief organizational development officer, associate director of an educational resource program at Harvard Medical School, and bestselling author of “Getting to G.R.E.A.T. 5-Step Strategy for Work and Life.” "The harder a decision is to make.....  STOP and take time to listen to your inner voice."   Madelaine shares her full story in her interview and points you to building your best adventures in life.  I"A great life depends on a great fit between who we are and the environments in which we work and live." Getting to G.R.E.A.T. is a lively, practical guidebook for living with a proven method that has already changed so many lives. Loaded with science and stories, each information-packed chapter launches with a topic-relevant vignette from the author's own experience, moves to research and practical recommendations on each chapter topic, and concludes with a chapter-specific case example and exercise for personal use.   Beginning with the pivotal event that shaped the trajectory of her work and life, Madelaine Weiss reveals a powerfully effective five-step strategy for satisfaction and success in your own work and life.   DIVE INTO A WORLD WHERE YOU AND YOUR BRAIN TEAM UP TO BUILD THE STORIES OF YOUR LIFE!

Paige Velasquez Budde is a veteran marketer, entrepreneur, author and keynote speaker.She is a co-founding partner and the CEO of Zilker Media, an Austin-based agency that builds trusted companies and leaders. During her tenure as CEO, the Austin Business Journal has named Zilker Media one of the city's fastest-growing companies as well as one of its best places to work, two years in a row. It has also been listed on Austin Inno's list of “Coolest Companies.”Paige is the author of the forthcoming book The Strategic Business Influencer: How to Build a Big Brand with a Small Budget (launching November 2025), which offers a research-backed framework to help business leaders create scalable, trust-based influence, even without big budgets. The book includes case studies from entrepreneurs across multiple industries and introduces Paige's signature concept: the Influence ID.She speaks to leaders about strategic business influence and people-driven marketing at many conferences and corporate events, including organizations such as Ernst & Young, JPMorgan Chase, Harvard Medical School, The University of Texas, Camp Gladiator, Entrepreneurs Organization, and the Women Presidents Organization. She delivered a TEDx Talk at the University of Texas Business School in March 2023. Her approach to people-driven marketing has been featured in media outlets such as Inc., Thrive Global, KevinMD, Texas CEO Magazine, Authority Magazine, Business News Daily, and Business.com.She has led marketing campaigns and strategies for some of the world's most recognized authorities. She has been named a finalist for the Austin Business Journal's Women in Business and Austin Under 40.Paige is passionate about community involvement and volunteers her time with several organizations. One is Texas Tower, a collegiate publicity organization for her alma mater, the University of Texas at Austin, where Paige teaches students about the PR and marketing industry. Paige loves spending time mentoring aspiring women entrepreneurs and leaders through programs like Kendra Scott's Entrepreneurial Leadership Institute at The University of Texas at Austin and ABBA's Emerging Leaders Initiative. She is also a member of Entrepreneurs Organization, Women Presidents Organization, C12, and the Austin Business Journal BizWomen Leadership Council. She resides west of Austin in Dripping Springs with her husband, Jordan and son, Landry.To learn more about her book and resources, visit www.paigevelasquezbudde.comhttps://zilkermedia.com/Influential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-paige-velasquez-budde-co-founding-partner-and-ceo-of-zilker-media

In this essential episode of Parallax, Dr Ankur Kalra is joined by Dr Carolyn Ho, Professor of Medicine at Harvard Medical School and Medical Director of the Cardiovascular Genetics Program at Brigham and Women's Hospital, for a comprehensive discussion on how genetic testing is reshaping hypertrophic cardiomyopathy management. The conversation explores the VANISH HCM trial results, which showed that valsartan can slow disease progression in young, asymptomatic individuals with early sarcomeric HCM. Dr Ho discusses how this evidence influenced the 2024 HCM guidelines and created new opportunities for disease-modifying therapy before clinical symptoms appear. The episode also examines emerging gene-based therapeutics, from current adeno-associated virus approaches to future CRISPR technologies that could address the underlying genetic causes of HCM. Dr Ho addresses practical considerations for clinicians, including when to initiate genetic testing, how to manage family screening, and the promise of AI-assisted screening tools. The discussion highlights both current therapeutic options and the evolving landscape of precision medicine in inherited cardiovascular disease. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Today's episode is going to focus on ligament reconstruction in skeletally immature patients – including various growth plate sparing ACL reconstruction techniques, MPFL reconstruction considerations and clinical outcomes.We are joined today by two outstanding guests! Dr. Mininder Kocher is a professor of orthopedic surgery at Harvard Medical School, Chief of Sports Medicine and Director of the Sports Medicine Fellowship at Boston Children's Hospital. He is the former President of PRISM and POSNA, and serves on the board of directors for AAOS and AOSSM.Dr. Lauren Redler is an assistant professor of orthopedic surgery at Columbia University Irving Medical Center and is actively involved in medical student, resident and fellow education at Columbia Ortho. She has published extensively on surgical treatment of ACL tears and patellar instability in pediatric patients, and is presenting her research on outcomes of MPFL reconstruction in skeletally immature patients at AOSSM this year!So, without further ado, let's get to the Exhibit Hall!

What if anxiety isn't something to fight, but something to work with? Dr. David Rosmarin believes anxiety is a natural emotion, not a disorder to fix. He shares a simple four-step process that helps you stop running from it: get honest about the cause, talk to someone, lean into the feeling, and drop the need to control everything. He also explains how tech, pressure, and even well-meaning parenting have made anxiety more intense for all of us, especially kids. If you're tired of trying to “get rid of” anxiety and ready to handle it differently, this conversation offers a healthier way through.   About David H. Rosmarin, PhD: David H. Rosmarin, PhD, is an Associate Professor at Harvard Medical School, a program director at McLean Hospital, and the Founder of Center for Anxiety. Through his work as a clinical psychologist, scientist, educator, author, and keynote speaker, David has helped thousands of individuals and organizations to thrive by embracing the emotion of anxiety. His clinical work and research have been featured in Good Morning America, the New York Times, the Wall Street Journal, the Boston Globe, and TED.com. Connect with David H. Rosmarin, PhD: Website: www.dhrosmarin.com Connect with Anna: Email: annamarie@happywholeyou.com / info@HappyWholeYou.com Website: www.happywholeyou.com / https://linktr.ee/happywholeyou Personal Website: www.DrAnnaMarie.com Instagram: @happywholeyou Personal Instagram: @Dr.Anna.Marie Facebook: Happy Whole You LinkedIn: Anna Marie Frank Venmo: @happywholeyou

Paige Velasquez Budde is a veteran marketer, entrepreneur, author and keynote speaker.She is a co-founding partner and the CEO of Zilker Media, an Austin-based agency that builds trusted companies and leaders. During her tenure as CEO, the Austin Business Journal has named Zilker Media one of the city's fastest-growing companies as well as one of its best places to work, two years in a row. It has also been listed on Austin Inno's list of “Coolest Companies.”Paige is the author of the forthcoming book The Strategic Business Influencer: How to Build a Big Brand with a Small Budget (launching November 2025), which offers a research-backed framework to help business leaders create scalable, trust-based influence, even without big budgets. The book includes case studies from entrepreneurs across multiple industries and introduces Paige's signature concept: the Influence ID.She speaks to leaders about strategic business influence and people-driven marketing at many conferences and corporate events, including organizations such as Ernst & Young, JPMorgan Chase, Harvard Medical School, The University of Texas, Camp Gladiator, Entrepreneurs Organization, and the Women Presidents Organization. She delivered a TEDx Talk at the University of Texas Business School in March 2023. Her approach to people-driven marketing has been featured in media outlets such as Inc., Thrive Global, KevinMD, Texas CEO Magazine, Authority Magazine, Business News Daily, and Business.com.She has led marketing campaigns and strategies for some of the world's most recognized authorities. She has been named a finalist for the Austin Business Journal's Women in Business and Austin Under 40.Paige is passionate about community involvement and volunteers her time with several organizations. One is Texas Tower, a collegiate publicity organization for her alma mater, the University of Texas at Austin, where Paige teaches students about the PR and marketing industry. Paige loves spending time mentoring aspiring women entrepreneurs and leaders through programs like Kendra Scott's Entrepreneurial Leadership Institute at The University of Texas at Austin and ABBA's Emerging Leaders Initiative. She is also a member of Entrepreneurs Organization, Women Presidents Organization, C12, and the Austin Business Journal BizWomen Leadership Council. She resides west of Austin in Dripping Springs with her husband, Jordan and son, Landry.To learn more about her book and resources, visit www.paigevelasquezbudde.comhttps://zilkermedia.com/Influential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-paige-velasquez-budde-co-founding-partner-and-ceo-of-zilker-media

In this JCO Article Insights episode, Michael Hughes summarizes “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I am interviewing Dr. Nikhil Munshi on the “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma” by Avet-Loiseau et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. While some patients with multiple myeloma live for decades after treatment, others exhibit refractory or rapidly relapsing disease irrespective of treatment administered. We term this “high-risk myeloma.” Multiple risk stratification systems have been created, starting with the Durie-Salmon system in 1975 and evolving with the advent of novel therapeutics and novel treatment approaches. In 2015, the Revised International Staging System (R-ISS) was introduced, which incorporated novel clinical and cytogenetic markers and remained, until recently, a mainstay of risk stratification in newly diagnosed disease. Myeloma as a field has, just in the past few years, though, undergone explosive changes. In particular, we have seen groundbreaking advances not only in treatments - the introduction of anti-CD38 agents and the advent of cellular and bispecific therapies - but also in diagnostic technology and our understanding of the genetic lesions in myeloma. This has led to the proliferation of numerous trials employing different definitions of high-risk myeloma, a burgeoning problem for patients and providers alike, and has prompted attempts to consolidate definitions and terminology. Regarding cytogenetic lesions, at least, Kaiser et al's federated meta-analysis of 24 therapeutic trials, published here in the JCO in February of 2025 and recently podcasted in an interview with associate editor Dr. Suzanne Lentzsch, posited a new cytogenetic classification system to realize a shared platform upon which we might contextualize those trial results. This article we have here by Dr. Avet-Loiseau, Dr. Munshi, and colleagues, published online in early June of this year and hot off the presses, is the definitive joint statement from the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG). What is high-risk multiple myeloma for the modern era? The IMS and IMWG Genomics Workshop was held in July 2023 and was attended by international myeloma experts, collaborating to reach consensus based on large volumes of data presented and shared. The datasets included cohorts from the Intergroupe Francophone du Myélome (IFM); the HARMONY project, comprised of multiple European academic trials; the FORTE study, findings from which solidified KRd as a viable induction regimen; the Grupo Español de Mieloma Múltiple (GEM) and the PETHEMA Foundation; the German-Speaking Myeloma Multicenter Group (GMMG); the UK-based Myeloma XI, findings from which confirmed the concept of lenalidomide maintenance; Emory 1000, a large, real-world dataset from Emory University in Atlanta; the Multiple Myeloma Research Foundation Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) dataset; and some newly diagnosed myeloma cohorts from the Mayo Clinic. Data were not pooled for analyses and were assessed individually - that is to say, with clear a priori understanding of whence the data had been gathered and for what original purposes. Consensus on topics was developed based on the preponderance of data across studies and cohorts. In terms of results, substantial revisions were made to the genomic staging of high-risk multiple myeloma, and these can be sorted into three major categories: A) alterations to the tumor suppressor gene TP53; B) translocations involving chromosome 14: t(14;16) (c-MAF overexpression), t(14;20) (MAFB overexpression), and t(4;14) (NSD2 overexpression); and C) chromosome 1 abnormalities: deletions of 1p or additional copies of 1q. In terms of category A, TP53 alterations: Deletion of 17p is present in up to 10% of patients at diagnosis and is enriched in relapsed or refractory disease. This is well-documented as a high-risk feature, but the proportion of the myeloma cells with deletion 17p actually impacts prognosis. GEM and HARMONY data analyses confirmed the use of 20% clonal cell fraction as the optimal threshold value for high-risk disease. That is to say, there must be the deletion of 17p in at least 20% of the myeloma cells on a FISH-analysis of a CD138-enriched bone marrow sample to qualify as high-risk disease. TP53 mutations can also occur. Inactivating mutations appear to have deleterious effects similar to chromosomal losses, and the biallelic loss of TP53, however it occurs, portends particularly poor prognosis. This effect is seen across Myeloma XI, CoMMpass, and IFM cohorts. Biallelic loss is rare, it appears to occur in only about 5% of patients, but next-generation sequencing is nevertheless recommended in all myeloma patients. Category B, chromosome 14 translocations: Translocation t(14;16) occurs in about 2% to 3% of patients with newly diagnosed disease. In the available data, primarily real-world IFM data, t(14;16) almost always occurs with chromosome 1 abnormalities. Translocation t(4;14) occurs in about 10% to 12% of newly diagnosed disease, but only patients with specific NSD2 alterations are, in fact, at risk of worse prognosis, which clinically appears to be about one in every three of those patients. And so together, the CoMMpass and Myeloma XI data suggest that translocation t(4;14) only in combination with deletion 1p or gain or amplification of 1q correlates with worse prognosis. Translocation t(14;20) occurs in only 2% of newly diagnosed disease. Similar to translocation t(4;14), it doesn't appear to have an effect on prognosis, except if the translocation co-occurs with chromosome 1 lesions, in which case patients do fare worse. Overall, these three translocations - t(14;16), t(4;14), and t(14;20) - should be considered high-risk only if chromosome 1 aberrations are also present. In terms of those chromosome 1 aberrations, category C, first deletions of 1p: Occurring in about 13% to 15% of newly diagnosed disease, deletion 1p eliminates critical cell checkpoints and normal apoptotic signaling. In the IFM and CoMMpass dataset analyses, biallelic deletion of 1p and monoallelic deletion of 1p co-occurring with additional copies of 1q denote high-risk. In terms of the other aberration in chromosome 1 possible in myeloma, gain or amplification of 1q: This occurs in up to 35% to 37% of newly diagnosed disease. It upregulates CKS1B, which is a cyclin-dependent kinase, and ANP32E, a histone acetyltransferase inhibitor. GEM and IFM data suggest that gain or amplification of 1q - there was no clear survival detriment to amplification - is best considered as a high-risk feature only in combination with the other risk factors as above. Now, in terms of any other criteria for high-risk disease, there remains one other item, and that has to do with tumor burden. There has been a consensus shift, really, in both the IMS and IMWG to attempt to develop a definition of high-risk disease which is based on biologic features rather than empirically observed and potentially temporally dynamic features, such as lactate dehydrogenase. Beta-2 microglobulin remains an independent high-risk indicator, but care must be taken when measuring it, as renal dysfunction can artificially inflate peripheral titers. The consensus conclusion was that a beta-2 microglobulin of at least 5.5 without renal failure should be considered high-risk but should not preclude detailed genomic profiling. So, in conclusion, the novel 2025 IMS-IMWG risk stratification system for myeloma is binary. It's either high-risk disease or standard-risk disease. It's got four criteria. Number one, deletion 17p and/or a TP53 mutation. Clonal cell fraction cut-off, remember, is 20%. Or number two, an IGH translocation - t(4;14), t(14;16), t(14;20) - with 1q gain and/or deletion of 1p. Or a monoallelic deletion of 1p with 1q additional copies or a biallelic deletion of 1p. Or a beta-2 microglobulin of at least 5.5 only when the creatinine is normal. This is a field-defining work that draws on analyses from across the world to put forward a dominant definition of high-risk disease and introduces a new era of biologically informed risk assessment in myeloma. Now, how does this change our clinical approach? FISH must be performed on CD138-enriched samples and should be performed for all patients. Next-generation sequencing should also be performed on all patients. Trials will hopefully now begin to include this novel definition of high-risk multiple myeloma. It does remain to be seen how data from novel therapeutic trials, if stratified according to this novel definition, will be interpreted. Will we find that therapies being evaluated at present have differential effects on myelomas with different genetic lesions? Other unanswered questions also exist. How do we go about integrating this into academic and then community clinical practice? How do we devise public health interventions for low-resource settings? To discuss this piece further, we welcome the esteemed Dr. Nikhil Munshi to the podcast. Dr. Munshi is a world-renowned leader in multiple myeloma and the corresponding author on this paper. As Professor of Medicine at Harvard Medical School, Director of the Multiple Myeloma Effector Cell Therapy Unit, and Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute, he has presided over critical discoveries in the field.  Thank you for joining us, Dr. Munshi. Dr. Nikhil Munshi: Oh, it's my pleasure being here, Michael, to discuss this interesting and important publication. Michael Hughes: I had a few questions for you. So number one, this is a comprehensive, shall we say, monumental and wide-ranging definition for high-risk myeloma. How do you hope this will influence or impact the ways we discuss myeloma with patients in the exam room? And how do we make some of these components recommended, in particular next-generation sequencing, feasible in lower-resource settings? Dr. Nikhil Munshi: So those are two very important questions. Let's start with the first: How do we utilize this in our day-to-day patient care setting? So, as you know well, we have always tried to identify those patients who do not do so well with the current existing treatment. And for the last 30 years, what constitutes a myeloma of higher risk has continued to change with improvement in our treatment. The current definition basically centers around a quarter of the patients whose PFS is less than 2 to 3 years. And those would require some more involved therapeutic management. So that was a starting point of defining patients and the features. As we developed this consensus amongst ourselves - and it's titled as “International Myeloma Society, International Myeloma Working Group Consensus Recommendation” - this IMS-IMWG type of recommendation we have done for many years, improvising in various areas of myeloma care. Now, here, we looked at the data that was existing all across the globe, utilizing newer treatment and trying to identify that with these four-drug regimens, with transplant and some of the immunotherapy, which group of patients do not do as well. And this is where this current algorithm comes up. So before I answer your question straight, “How do we use it?” I might like to just suggest, “What are those features that we have identified?” There are four features which constitute high-risk disease in the newer definition. Those with deletion 17p with 20% clonality and/or TP53 mutation. Number two, patients with one of the translocations - t(4;14), t(14;16), or t(14;20) - co-occurring with 1q amplification or deletion 1p32. And that's a change. Previously, just the translocation was considered high-risk. Now we need a co-occurrence for it to be called high-risk. The third group is patients having biallelic deletion 1p32 or monoallelic deletion 1p32 along with 1q amplification. And finally, patients with high beta-2 microglobulin, more than or equal to 5.5 mg/dL, with normal creatinine less than 1.2 mg/dL. And the question, “How do we use this?” There are multiple areas where we incorporate high-risk features in our treatment algorithm. One of the first areas is where we would consider the induction regimen. If a patient has a high-risk disease, we would definitely consider a four-drug regimen rather than a three-drug regimen, although we are beginning to incorporate four-drug for all groups. That's one important thing. Number two, those are the patients where we do consider consolidation with transplant or maybe in the new world, considering some of the immunotherapeutic consolidation more early or more aggressively. Number three, these are the patients who get a little bit more maintenance therapy. So normally, lenalidomide might end up being our standard maintenance regimen. In patients who have high-risk disease, we incorporate either addition of daratumumab or the anti-CD38 targeting antibody and/or addition of proteasome inhibitor, either bortezomib or carfilzomib. So you would have multi-drug maintenance therapy in these patients. And in high-risk patients, we follow them with maintenance longer periods of time. One very critically important point to keep in mind is that to get the better outcome in high-risk disease, we must try to get them into MRD negativity because there is clear data that patients who do achieve MRD negativity, despite having high-risk disease, have a much superior outcome. They become near to standard-risk disease. And so, in high-risk patients, I would try to do whatever various options I have to try and get them into MRD-negative status. And when these patients relapse, we do not wait for the classic progression criteria to be met before we intervene. We would propose and suggest that we intervene earlier before the disease really blasts off. And so there are a number of areas in our setting where this high-risk definition will help us intervene appropriately and also with appropriate aggressiveness to achieve better outcome, to make this similar to standard-risk disease. Michael Hughes: Thank you, Dr. Munshi. And thoughts on how to really integrate this not only into academic centers but also lower-resource settings? Dr. Nikhil Munshi: So that's a very important question, Michael. And when we were developing this consensus, we were very cognizant of that fact. So wherever available, I think we are recommending that over a period of next 2, 3, 5 years, we should begin to switch over to sequencing-based methods because two components of this definition, one is TP53 mutation, which we cannot do without sequencing, and also reliably detecting deletion 1p requires sequencing-based method. So in the low-resource countries - and there are many in this world, and also even in our own country, patients may not be able to afford it - the older method with FISH or similar such technology, which is more affordable, is also acceptable for current time. They may miss a very small number of patients, maybe 2% to 3%, where these finer changes are not picked up, but a majority of this would be captured by them. So the current practice might still be applicable with some limitation in those patient populations, and that's what we would recommend. What is happening, fortunately, is that actually sequencing-based method is becoming cheaper. And in many centers, it is cheaper to do the sequencing rather than to do the FISH analysis. And so my hope is that even in low-resource centers, sequencing might be more economical in the end. It's, I think, the access to technology, which is a little bit limited currently, but it's hopefully becoming available soon. Michael Hughes: Thank you, Dr. Munshi. And staying for a minute and looking at the multiple myeloma subsets which might be missed by this really still very broad-ranging high-risk definition, at least by prior risk stratification systems, right, there is this group of patients who have standard-risk cytogenetics by R-ISS or R2-ISS, but they have primary refractory disease or they relapse early. We call these, as you are well aware, functionally high-risk disease. What proportion of previously FHR, functionally high-risk, myeloma patients do you expect to be captured by this novel definition? Dr. Nikhil Munshi: So I think the newer definition - and we can look at it both ways, but the newer definition should capture most of the functionally high-risk definition. To put it differently, Michael, there are patients who we know are, as you mentioned, functionally high-risk. Those are the patients who might have plasma cell leukemia, those who might have extramedullary disease, those who might not respond to our four-drug induction. If you don't respond to the four-drug induction, almost by definition, they are high-risk. However, a majority of them have one of the abnormalities that we are describing here. There would be a very small proportion which may not have. And if they do not have, we know one of the important components of this definition here is also that the genome, we know, keeps on evolving. So there may be a very small clone with the high-risk feature which was not obvious in the beginning. Following treatments or following relapse, that clone predominates, and now the patient's disease becomes high-risk.  So the definition would incorporate or would capture these functional high-risk patients, but as you said, in countries where resources are not available, using this functional high-risk would also be helpful and advantageous. Sometimes LDH ends up being a high-risk. In our studies, LDH has not come out to be high-risk anymore because the features we are describing captures most of those patients, but those alternatives, older, can still be considered if other newer techniques are not available. Michael Hughes: Got you. And in terms of these older definitions, yes, that incorporate tumor burden, these empirical observations about how myeloma presents, do you foresee any additional tumor burden indicators being added to future definitions of high-risk disease? Or do you instead see this particular definition as a major waypoint on the journey towards a fully biologically grounded definition of high-risk disease? Dr. Nikhil Munshi: I think your second part is what is going to happen. I think the tumor burden-related definition is being now replaced by the biological or genomic-based definition. And I think at some point, it will be quite fully replaced. One component not here, and it is because one thing, we don't have enough data; number two, we don't know how it will pan out, is also the influence of the microenvironment on the risk definition. For example, the immune system, the immune function, etc. But not enough data exists to suggest how it would change the current definition. So in future, would a definition be totally genomic or it could be more integrative? And my personal guess is that it would be more integrative and that some immune features might come into the picture, especially now that we are using immune-based therapy as a very important component of treatment - CAR T-cells, bispecific, and antibody-based treatments. What role the immune system plays in either supporting tumor or what role suppression of the anti-tumor immunity plays? They all will be important how patient outcomes end up being, and which in turn could translate into how patient's risk stratification might happen. So I think the older tumor burden-related definitions probably will become things of the past. What we have currently proposed and consensus developed is the new path forward, and over time, some microenvironmental influences, if defined and found to be important, may get some more incorporation if it compares favorably with the genomic features. Michael Hughes: Thank you, Dr. Munshi for that enlightening response.  To conclude the podcast, I'd like to look to the future and to the immediate future, what are the next steps for high-risk disease definition between now and discussing an integrated genomic-microenvironment-based definition? Will we see attempts to refine? Will we see a multi-level system, things like this? Dr. Nikhil Munshi: Yeah, so I think the current definition will be here to stay for the next 10 years or so. I think this has been developed using a large amount of data, so we do believe that this will remain fine. It has been validated now within the last six months by a few of the other studies. So there won't be a quick change. But we will try to, all of us will try to innovate. And as you very rightly bring up, the areas of research would include looking at the expression or transcriptomic component. Does that matter? And we do believe a small number of patients will have transcriptomic changes, not looked at the DNA changes, and may play a role. There are newer components, so long non-coding RNA, for example, is going to be an important component to look at, how it impacts the disease outcome, etc. There are also some of the proteomic-related changes which may become important in our studies. And then as we discussed, microenvironment and immunological changes. So these are the future areas of ongoing research where we all should collect data, and then in the next 5 to 10 years, we'll have another group meeting to see has anything changed or any of the features have become more important.  Most of the time, some of the older features are lost because they are not as critically high-risk, and the newer features come in. And so the historical background for just one second, there was a time when chromosome 13 was considered a high-risk disease. We now don't even mention it because it's not high-risk. The newer treatments have improved the outcome. t(4;14) used to be a high-risk disease. Now by itself today, in this definition by itself is not; it needs to be with something else. And so I think this is a great sign of progress. As we improve the treatment and outcomes, some of the features will become less important, new features will come up, and we'll need to keep on evolving with time and with technology and make it better for patients. Michael Hughes: Thank you so much, Dr. Munshi, for your wisdom, for your sagacity, for your historical perspective as well.  Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries. And be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

At the 2025 Kidney Cancer Research Summit hosted by KidneyCAN, CancerNetwork® spoke with a variety of leading experts about key developments in the research and management of kidney cancer. Throughout the meeting, presenters shared their findings related to updated clinical trial results, personalized cancer vaccines, potential biomarkers of interest, and other advancements in the field. Thomas Powles, MBBS, MCRP, MD, discussed outcomes from a quality-adjusted survival time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITESPARK-005 trial (NCT04195750), in which investigators evaluated treatment with belzutifan (Welireg) vs everolimus (Afinitor) among patients with advanced renal cell carcinoma (RCC). Powles, a professor of genitourinary oncology, lead for Solid Tumor Research, and director of Barts Cancer Institute at St. Bartholomew's Hospital, Queen Mary University of London, stated that these data demonstrate how belzutifan is more active and better tolerated than everolimus in this patient population. David A. Braun, MD, PhD, assistant professor at Yale School of Medicine and member of the Center of Molecular and Cellular Oncology within the Yale Cancer Center, detailed his presentation on a personalized neoantigen cancer vaccine as a treatment for those with RCC. Based on his presentation, Braun highlighted how neoantigen vaccines may effectively yield T-cell responses in patients, illustrating a need for additional, larger studies to elucidate the clinical activity of this modality in an adjuvant setting. Additionally, Wenxin (Vincent) Xu, MD, a medical oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, spoke about his presentation on how kidney injury molecule-1 (KIM-1) may serve as a prognostic biomarker of response to therapy in patients with RCC. His research posed questions on how KIM-1 can inform the use of adjuvant therapy or specific therapeutic combinations like nivolumab (Opdivo) plus ipilimumab (Yervoy) for this patient population. Eric Jonasch, MD, gave an overview of his presentation focused on the Kidney Cancer Research Consortium, a research partnership spanning 7 institutions dedicated to facilitating mechanistic, hypothesis-testing clinical trials in RCC. Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, described how this collaboration aims to link identifiable biological characteristics of RCC subtypes to specific treatment strategies while developing predictive biomarkers. KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding. You can learn more about KidneyCAN's work here: https://kidneycan.org/ References 1. Powles T, de Velasco G, Choueiri TK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005). Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. Abstract 13. 2. Braun DA. Personalized vaccines in kidney cancer: a journey from concept to clinic. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 3. Xu W. From bench to bedside: advancing KIM-1 as a tool for clinical decision-making. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 4. Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

Send us a textWe dive deep into how digital algorithms shape our thinking and behavior through subtle reward systems rather than direct commands, exploring Michael Aponte's concept of "digitally optimized obedience" and its far-reaching implications for individual autonomy and society. Drawing from Aponte's research, the Meadows Mental Health Policy Institute, and Harvard Medical School findings, we examine how technology is fundamentally reshaping our sense of morality and acceptable speech through invisible algorithmic nudges.• Digitally optimized obedience works through rewards and incentives, not direct commands or fear• Algorithms create feedback loops that train users to behave in ways that generate engagement • Content amplification functions as implicit moral approval while shadow-banning marks ideas as unacceptable• Echo chambers and filter bubbles create the illusion of information while narrowing our perspectives• Algorithms deliberately escalate content toward more extreme versions to maintain engagement• Digital platforms known to target children's developing brains despite awareness of potential harm• Self-censorship emerges as users internalize algorithmic preferences to gain social rewards• Reclaiming autonomy requires conscious awareness of how algorithms shape our choicesTake a moment to consider how deeply algorithms are influencing your thoughts and behaviors. What does genuine freedom of choice look like in our digitally optimized world? Please like, comment, share, and subscribe to Thinking2Think for more explorations into the forces shaping our minds.Support the show

Imagine practicing medicine not within the sterile confines of a hospital, but in the unpredictable world of city streets and shelters, where every patient encounter challenges conventional notions of care, empathy, and human dignity. We explore this reality through the extraordinary journey of Jim O'Connell, MD, whose groundbreaking work with Boston's homeless population has profoundly reshaped health care for society's most marginalized individuals.Dr. O'Connell is the founding president of the Boston Healthcare for the Homeless Program and an assistant professor of medicine at Harvard Medical School. In this episode, Dr. O'Connell shares stories from his extensive frontline experience, detailing the unique challenges of treating patients facing complex medical and psychiatric conditions exacerbated by unstable living conditions. From addressing devastating public health crises such as AIDS and tuberculosis to establishing consistent mental health care, he provides profound insights into what makes healthcare effective for homeless populations. He also reflects on a formative early experience — being asked by nurses to wash patients feet — that deeply influenced his understanding of empathy and the essence of medical service. Through these reflections, we gain a powerful appreciation for the depth of patience, relational care, and respect required in caring for vulnerable communities. In this episode, you'll hear about: 2:00 - Dr. O'Connell's unexpected path to medicine11:34 - The distinction between a “country doctor” and a doctor who works in an academic setting13:42 - How Dr. O'Connell began working with homeless populations 20:30 - The difficulties doctors faced in the early years of the HIV/AIDS epidemic29:14 - Navigating the compounding challenges of access and continuity among the homeless population 37:12 - What has kept Dr. O'Connell dedicated to treating this population for 30+ years 51:24 - Dr. O'Connell's recommendations to clinicians on how to compassionately serve the homeless Visit our website www.TheDoctorsArt.com where you can find transcripts of all episodes.If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2025

Dr. Roberto Olivardia, a Clinical Instructor of Psychology at Harvard Medical School, talks about the relationship between ADHD and sleep challenges, and offers strategies for children struggling with sleep. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Hoje recebemos o Dr Marcos Ávila especialista em retina pela Harvard Medical School, professor Titular de Oftalmologia da FM/UFG 1997, Ex presidente da SBRV, Ex presidente do CBO. E também recebemos o Dr Lucas Zago que é especialista em retina pela EPM e Coordenador Médico do Programa Olhar para Todos.No Episódio de hoje conhecemos os bastidores do Programa Olhar Para Todos: Um programa do Governo de Goiás que oferece atendimento oftalmológico gratuito a estudantes da rede pública estadual, incluindo exames, diagnóstico, entrega de óculos e encaminhamento para tratamentos, quando necessário. Já beneficiou mais de 20 mil alunos, visando melhorar o desempenho escolar e reduzir a evasão. A iniciativa, realizada em parceria com a UFG, SEDUC e OVG, pretende atender todos os mais de 495 mil estudantes até 2026. Material Suplementar:Livro: Saúde Ocular no SUS Vídeo sobre o projetoSite do Projeto Olhar Para TodosDetalhes sobre o Projeto:O Projeto tem objetivo de promover saúde ocular gratuita aos estudantes, por meio de avaliação, diagnóstico, acompanhamento especializado e entrega gratuita de óculos.O Governo de Goiás, por meio da Secretaria de Estado da Saúde (SES), em parceria com o Centro de Referência em Oftalmologia da Universidade Federal de Goiás (Cerof/UFG), Secretaria de Estado da Educação (SEDUC) e Organização das Voluntárias de Goiás (OVG), já atendeu 20.062 estudantes da rede pública estadual nos últimos 7 meses. O número corresponde a 64,1% dos alunos das escolas visitadas e que tiveram autorização dos pais/responsáveis.O Olhar Para Todos, lançado em novembro de 2024, é considerado o maior programa público de saúde oftalmológica do Centro-Oeste. Por meio de um consultório móvel, a ação disponibiliza oftalmopediatras e equipamentos de ponta nas escolas para realização de exames e, se necessário, oferta de óculos e/ou encaminhamento, via regulação estadual, para acompanhamento ambulatorial ou cirúrgico pelo Sistema Único de Saúde (SUS).O programa já esteve em 59 escolas da rede estadual de educação e encaminhou 1.201 estudantes para acompanhamento no Cerof/GO que oferece atendimento especializado em problemas oculares, como glaucoma, estrabismo, córnea, retina e outros. Dentre os estudantes atendidos 6.428 precisavam da prescrição de óculos, os quais foram ofertados pela OVG.O objetivo é estender a ação aos mais de 495 mil estudantes até 2026. A presidente de honra da OVG, primeira-dama Gracinha Caiado, destacou o alcance do programa Olhar Para Todos. “Não fazemos apenas o exame. Quem precisa de cirurgia também é atendido. “Fazemos isso para mostrar que não existe governo se não for para cuidar das pessoas”, afirmou.Segundo dados do Governo de Goiás, programas de exames e doação de óculos podem reduzir em 12% a repetência e a evasão escolar. O Secretário de Estado da Saúde, Rasível Santos, enfatizou a importância do projeto. “O Olhar para Todos assegura que os estudantes tenham acesso a consultas oftalmológicas e tratamentos necessários, garantindo melhores condições para alcançar bons resultados acadêmicos”, acrescentou.De acordo com o presidente do conselho administrativo do Cerof/UFG, Marcos Ávila, a iniciativa leva até a comunidade escolar consultórios modernos e completos, dispostos em ônibus, para oferecer atendimento de qualidade aos jovens pacientes. “Esse projeto é inovador em termos de diminuir a repetência, a evasão e tantos problemas que quem não enxerga enfrenta em uma sala de aula”, destacou. 

We're discussing Taking Care: of Ourselves, Each Other, and Our System! Faisel and Dan are joined by Dr. Asaf Bitton, executive director of Ariadne Labs and Associate Professor of Medicine and Health Care Policy at Harvard Medical School and Harvard T.H. Chan School of Public Health.Our conversation revolves around innovating payment models beyond units, taking responsibility for patient needs beyond clinic visits, and efficiently connecting with patients and colleagues beyond bare necessity.

Eben Alexander, MD, was an academic neurosurgeon for over 25 years, including 15 years at the Brigham & Women's Hospital, Children's Hospital, and Harvard Medical School in Boston. He experienced a transcendental Near-Death Experience (NDE) during a week-long coma from an inexplicable brain infection that completely transformed his worldview. A pioneering scientist and modern thought leader in the emerging science that acknowledges the primacy of consciousness in the universe, he is the author of the New York Times #1 Bestseller Proof of Heaven, The Map of Heaven and Living in a Mindful Universe. Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

Guest: Eben Alexander, MDFull Notes: Neurosurgeon Gets “Proof” of an Afterlife with Eben Alexander, MD - Episode 145Eben Alexander, MD was an academic neurosurgeon, including teaching neurosurgery at Harvard Medical School. A staunch materialist, his world-view changed when he had an NDE after bacterial meningo-encephalitis put him into a coma for 7 days. He's author of a series of books including “Proof of Heaven.” FULL BIO + SHOW NOTESJoin our Science + Spirituality CircleHost or Attend a Science + Spirituality SalonBuy the books: ⁠⁠WTF Just Happened?! SeriesFollow Dr. Eben Alexander: Website | YouTube**I hope to see you at the IANDS Conference!!**IANDS : INTERNATIONAL ASSOCIATIONAttend the Conference Support IANDS⁠⁠⁠Buy me a coffee⁠⁠⁠⁠ |⁠⁠ ⁠⁠WTF Just Happened Books⁠⁠ | ⁠⁠⁠⁠Science + Spirituality Salons⁠⁠ |⁠⁠⁠⁠Newsletter ⁠⁠⁠ |Patreon 

Headaches: Why You Have Them What you Can Do About Them by Egilius L.H. Spierings, BS,MS,MD,PhDThis book is primarily for those afflicted by headaches, particularly intense headaches like migraine.However, it also deals with other headache conditions, such as cluster headache, concussion headache, and headache in pregnancy as well as with face pain.Dr. Spierings is a pharmacologist, neurologist, headache and face pain specialist, and clinical trialist. He was born in Helmond, the Netherlands, in 1953. He attended the Erasmus University Faculty of Medicine in Rotterdam, the Netherlands, where he received bachelor's and master's degrees in medical sciences, a medical doctor degree, and a doctor of philosophy degree in experimental pharmacology.In terms of postgraduate education, he trained in neurology and neurosurgery at the University Hospital Dijkzigt, now Erasmus Medical Center, in Rotterdam, the Netherlands; in psychiatry at the Reinier de Graaf Gasthuis in Delft, the oldest hospital in the Netherlands; and in headache management at the Headache Research Foundation at Faulkner Hospital in Boston, Massachusetts.He was a professor of neurology and craniofacial pain, part-time academic faculty, at Tufts University Schools of Medicine and Dental Medicine until he retired from academia in 2018. Since, he has been the medical director of the Boston Headache Institute and MedVadis Research at Boston Advanced Medicine, formerly Boston PainCare, in Waltham, Massachusetts.Egilius L. H. Spierings, BS, MS, MD, PhD Medical director at Boston Headache Institute and MedVadis Research, Boston Advanced Medicine, Waltham, Massachusetts Retired clinical professor of neurology and craniofacial pain at Tufts University Schools of Medicine and Dental Medicine, Boston, Massachusetts Former associate clinical professor of neurology at Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts AMAZONhttps://www.help4headache.com/https://citiofbooks.comhttp://www.bluefunkbroadcasting.com/root/twia/72425cob.mp3 

Send us a textDr. On-Yee (Amy) Lo, Ph.D. is Assistant Scientist II at the Marcus Institute for Aging Research ( https://www.marcusinstituteforaging.org/who-we-are/profiles/yee-amy-lo-phd ) and Assistant Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center ( https://connects.catalyst.harvard.edu/Profiles/display/Person/147630 ).Dr. Lo is a physical therapist and research scientist who aims to prevent functional decline and enhance functional independence for older adults with mobility impairments by conducting experimental and translational research. She has expertise and experience in physical therapy, biomechanics, neuroimaging, and neuromodulation.Dr. Lo has dedicated her career to enhancing functional independence and quality of life in older adults. Her specific research objectives are:  - To investigate connections between the brain and body that enable safe navigation throughout daily environments.- To innovate rehabilitative interventions that target these brain and body connections to preserve and restore the control of mobility.- To implement the experimental findings into the clinical setting.Dr. Lo's clinical and scientific training in physical therapy, biomechanics, neurophysiology, neuroimaging, neuromodulation, and gerontology have enabled her to cultivate her passions in conducting translational research to help older adults walk and move safely in real life. She incorporates cognitive, brain, and movement sciences to understand the complex control of gait and mobility, and develop individualized, multi-modal, and patient-centered interventions that can both stand alone and be combined with current evidence-based geriatric rehabilitation programming to improve mobility and mitigate fall risks in older adults. Dr. Lo has a Master of Arts (M.A.) in Pathokinesiology from New York University and a Doctor of Philosophy (Ph.D.), Human Physiology from University of Oregon.#PhysicalTherapy #Biomechanics #Neurophysiology #Neuroimaging #Neuromodulation #Gerontology #TranscranialDirectCurrentStimulation #Gait #Mobility #GeriatricRehabilitation #Cognition #Pathokinesiology #HumanPhysiology #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

In this episode of The Bulletin, producer Clarissa Moll talks with missiologist Todd Korpi about what AI reveals about being human. Associate producer Alexa Burke digs into artificial intelligence history with data science professor Jonathan Barlow, and Dr. Finny Kuruvilla shares the amazing advancements and ethical questions that AI in medical technology raises.  GO DEEPER WITH THE BULLETIN: -Join the conversation at our Substack. -Find us on YouTube. -Rate and review the show in Apple Podcasts. ABOUT THE GUESTS:   Todd Korpi is a Pentecostal missiologist, researcher, and writer. In addition to work consulting with churches on organizational effectiveness and missional engagement, he serves as lead researcher of the Digital Mission Consortia at the Wheaton College Billy Graham Center and as an adjunct instructor in mission and leadership at several institutions. Jonathan Barlow is associate director of the Data Science program at Mississippi State as well as an assistant teaching professor. Previously, Barlow was an associate director at NSPARC, a research center at Mississippi State University. With a background in industry and university research, Barlow has more than 25 years of experience in software development, data modeling, data-intensive applications, and data analysis. His research interests involve natural language processing and the ethics of artificial intelligence. Finny Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry. He is the co-chief investment officer at Eventide Asset Management, LLC, a socially-responsible and values-based investing firm.   Views expressed in this podcast are intended for information purposes and do not constitute investment advice. Eventide does not provide tax, accounting, or legal advice. Eventide's values-based approach to investing may not produce desired results and could result in underperformance compared with other investments. There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. ABOUT THE BULLETIN: The Bulletin is a twice-weekly politics and current events show from Christianity Today moderated by Clarissa Moll, with senior commentary from Russell Moore (Christianity Today's editor in chief) and Mike Cosper (director, CT Media). Each week, the show explores current events and breaking news and shares a Christian perspective on issues that are shaping our world. We also offer special one-on-one conversations with writers, artists, and thought leaders whose impact on the world brings important significance to a Christian worldview, like Bono, Sharon McMahon, Harrison Scott Key, Frank Bruni, and more.  The Bulletin listeners get 25 percent off CT. Go to https://orderct.com/THEBULLETIN to learn more. “The Bulletin” is a production of Christianity Today Producer: Clarissa Moll Associate Producer: Alexa Burke Editing and Mix: Kevin Morris Music: Dan Phelps Executive Producers: Erik Petrik and Mike Cosper Senior Producer: Matt Stevens Learn more about your ad choices. Visit podcastchoices.com/adchoices

Emily Kircher-Morris talks with Dr. Christopher Willard, a clinical psychologist and author, about the complexities of life's major transitions. At this time of year, this is an especially-important conversation, as some students prepare for the shift to college life. They share their own experiences and provide advice on navigating the pressures of newfound independence, the importance of self-care, and the role of systemic support in easing major transitions. Yes, they also talk about farts, so this episode has something for everyone. TAKEAWAYS It's important to understand the mental health challenges that often arise during major life transitions. There's a role for social media in destigmatizing mental health issues, but it also spreads misinformation. Systemic support is essential in educational institutions, in order to better assist students, especially those from marginalized communities. It's important not to over-pathologize normal emotional experiences. There was a creative process behind Dr. Willard's children's book, "Feelings Are Like Farts," which uses humor to engage kids in understanding emotions. Let the courses in the Neurodiversity University help you be a better educator, parent, and/or clinician. Dr. Christopher Willard is a clinical psychologist, author, and consultant based in Massachusetts, with a global presence as a speaker in over 40 countries and two TEDx events. He is the author of 20 books on mental health and mindfulness, including Alphabreaths, Growing Up Mindful, Feelings Are Like Farts, and the upcoming College Mental Health 101 (2025). Dr. Willard's work has been featured in The New York Times, The Washington Post, CNN.com, and mindful.org. In addition to his clinical and writing work, he teaches at Harvard Medical School, where he continues to shape conversations around mindfulness, emotional well-being, and mental health in education and beyond. BACKGROUND READING Chris's website, Instagram, Facebook, Feelings Are Like Farts The Neurodiversity Podcast is on Facebook, Instagram, BlueSky, and you're invited to join our Facebook Group.

*As featured in the streaming documentary #UNTRUTH—now with a new foreword by George Conway and an afterword by the author*A masterful and eye-opening examination of Trump and the coercive control tactics he uses to build a fanatical devotion in his supporters written by “an authority on breaking away from cults…an argument that…bears consideration as the next election cycle heats up” (Kirkus Reviews). Since the 2016 election, Donald Trump's behavior has become both more disturbing and yet increasingly familiar. He relies on phrases like, “fake news,” “build the wall,” and continues to spread the divisive mentality of us-vs.-them. He lies constantly, has no conscience, never admits when he is wrong, and projects all of his shortcomings on to others. He has become more authoritarian, more outrageous, and yet many of his followers remain blindly devoted. Scott Adams, the creator of Dilbert and a major Trump supporter, calls him one of the most persuasive people living. His need to squash alternate information and his insistence of constant ego stroking are all characteristics of other famous leaders—cult leaders.In The Cult of Trump, mind control and licensed mental health expert Steven Hassan draws parallels between our current president and people like Jim Jones, David Koresh, Ron Hubbard, and Sun Myung Moon, arguing that this presidency is in many ways like a destructive cult. He specifically details the ways in which people are influenced through an array of social psychology methods and how they become fiercely loyal and obedient. Hassan was a former “Moonie” himself, and he presents a “thoughtful and well-researched analysis of some of the most puzzling aspects of the current presidency, including the remarkable passivity of fellow Republicans [and] the gross pandering of many members of the press” (Thomas G. Gutheil, MD and professor of psychiatry, Harvard Medical School). The Cult of Trump is an accessible and in-depth analysis of the president, showing that under the right circumstances, even sane, rational, well-adjusted people can be persuaded to believe the most outrageous ideas. “This book is a must for anyone who wants to understand the current political climate” (Judith Stevens-Long, PhD and author of Living Well, Dying Well).https://amzn.to/4kQXbhkBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-opperman-report--1198501/support.

More than a thousand AI medical devices have FDA clearance, yet fewer than two percent of radiologists actually use them.In this episode, Steve sits down with Dr. Brian Anderson—CEO and co‑founder of the Coalition for Health AI—to unpack why trust, transparency, and regulation could make or break the next wave of AI‑powered medicine.We cover:

Margaret Moore, faculty member at Harvard Medical School and former biotech CEO, brings decades of experience at the intersection of science, strategy, and human development to this conversation. In this episode, she unpacks The Science of Leadership, the forthcoming book she co-authored after reviewing hundreds of meta-analyses and large-scale studies, ultimately synthesizing leadership science into a framework of nine essential capacities.   Moore emphasizes the role of conscious leadership, defined as the ability to “see things clearly” by quieting internal “ego noise”, the arousal, impatience, and worry that cloud judgment. She highlights the emerging concept of the quiet ego, noting that “you're still impactful... but with a way of being quiet about it that people can absorb more easily.”   Challenging conventional strength-based approaches, Moore advocates for psychological wholeness, encouraging leaders to access underused capacities—such as empathy, creativity, and intuition—to become more balanced and mature decision-makers: “You'll be surprised that you have it there… You actually, if you pause, can access [it], like playing or being an orchestra conductor.”   She also discusses how intuition, often misunderstood as abstract, is a skill that can be developed through stillness, reflection, and experience: “Creativity is flow, and flow is when you let go of control… It's the opposite of our main mode.”   The conversation underscores the importance of strategic adaptability. Drawing on research, Moore shares that while humility doesn't improve a leader's own performance, “other people's performance is improved if you're humble. So you don't do it for yourself, you do it for them.” But she also cautions: in crises, “humility is not what people want. They want strong leaders out in front, in charge.”   Finally, Moore distinguishes between empathy and compassionate leadership, where compassion is “respect and understanding… with action,” and can be both more sustainable and effective in driving accountability.   For leaders ready to evolve beyond performance and toward genuine transformation, this conversation offers a research-grounded framework and an invitation to reflect: “In the moment, there's always the potential. If you're just awake, you will feel it. And you can act on it.”   Get Margaret's book here: https://shorturl.at/tuRKR The Science of Leadership: Nine Ways to Expand Your Impact   Here are some free gifts for you:   Overall Approach Used in Well-Managed Strategy Studies free download: www.firmsconsulting.com/OverallApproach   McKinsey & BCG winning resume free download: www.firmsconsulting.com/resumepdf   Enjoying this episode? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo

Join me, Seth Farbman, as we dive into the fascinating story behind YourBio Health, a medical device company that has created a revolutionary solution for blood draws. Hear from the impressive team of experts, including CEO, Paul Owen, with his 35 years of experience in the healthcare industry including the Mayo Clinic, Chief Medical Officer Dr. Robson with his background in leading clinical initiatives at Walgreens, and Chief Scientific Officer Dr. Mina, previously a professor at Harvard Medical School.

Dr. Uche Blackstock is the founder and CEO of Advancing Health Equity (AHE), appears regularly on MSNBC and NBC News, and is a former associate professor in the Department of Emergency Medicine and the former faculty director for recruitment, retention, and inclusion in the Office of Diversity Affairs at NYU School of Medicine.In 2019, Dr. Blackstock founded AHE which partners with organizations to drive measurable change in health outcomes by embedding equity into leadership, strategy, and clinical practice. In its five years of existence, AHE has helped major companies, hospitals, and health systems create strategic plans for promoting equitable health care moving for Dr. Blackstock's writing, including numerous OpEds, has been featured in the Chicago Tribune, Scientific American, the Washington Post and New York Magazine. She was recognized by Forbes magazine, in 2019, as one of “10 Diversity and Inclusion Trailblazers You Need to Get Familiar With", in 2023 by Fortune Magazine as one of & Innovators Shaping the Future of Health”, and in 2024, as one of TIME 100 Most influential People in Health.Dr. Blackstock received both undergraduate and medical degrees from Harvard University, making her and her twin sister, Oni, the first Black mother-daughter legacy graduates from Harvard Medical School. Dr. Blackstocks generational memoir, LEGACY: A Black Physician Reckons with Racism in Medicine was published by Viking Books on January 23, 2024 and became an instant New York Times best-seller.Dr. Blackstock currently lives in her hometown of Brooklyn, New York, with her two school-age children. How to advocate for your healthcare? How to cope with structural racism? What is bias in medicine? What healthcare disparaties? How are mental healthcare outcomes different across BIPOC populatons? How to feel supported as a Black physician? How to cope with burnout as a Black Physician. How to Cope with High Functioning Depression.Follow Dr. Uche Blackstock MD Dr. Uche Blackstock's Instagram https://www.instagram.com/ucheblackstockmd/ Dr. Uche Blackstock's Website https://ucheblackstock.com/ Dr. Uche Blackstock's LinkedIn https://www.linkedin.com/in/uche-blackstock-md/ Dr. Uche Blackstock's Book https://ucheblackstock.com/book/ Advancing Equity Website https://advancinghealthequity.com/Follow Dr. Judith:Instagram: https://instagram.com/drjudithjoseph TikTok: https://www.tiktok.com/@drjudithjoseph Facebook: https://www.facebook.com/drjudithjoseph Website: https://www.drjudithjoseph.com/Sign up for my newsletter here: https://www.drjudithjoseph.com/newsletter-sign-upDisclaimer: You may want to consider your individual mental health needs with a licensed medical professional. This page is not medical advice.

Welcome to Real Food Recovery, a podcast created by two lifelong processed food addicts with over 100 years of addiction (and recovery) between them. Paige Alexander and Jamie Morgan Reno use their Real Food Recovery podcast and social media channels to share their struggles, lessons learned, tools, tips, and resources that freed them from decades of food addiction, obsession, and loss.   Join us as we welcome back Dr. Roberto Olivardia for a deeper dive into all things ADHD. Dr. Olivardia is a Clinical Psychologist, Lecturer in Psychology in the Department of Psychiatry at Harvard Medical School and Clinical Associate at McLean Hospital. He maintains a private psychotherapy practice in Lexington, Massachusetts, where he specializes in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), Obsessive-Compulsive Disorder (OCD), and Body Dysmorphic Disorder (BDD), as well as issues that face students with learning disabilities.  He is a nationally recognized expert in eating disorders and body image problems in boys and men.  He is co-author of The Adonis Complex, the first book of its kind detailing male body image issues.  He has appeared in publications such as TIME, GQ, and Rolling Stone, and has been featured on Good Morning America, CNN, and VH1. You can find more about Dr. Olivardia here: https://www.mcleanhospital.org/profile/roberto-olivardia In every Real Food Recovery episode, Paige and Jamie take time to answer viewer questions about processed food addiction, obsession, and recovery, be sure to submit yours on their YouTube Channel or Facebook Page. You can also follow Real Food Recovery on Instagram (@realfoodrecovery4u), TikTok (@realfoodrecovery) or at www.realfoodrecovery4u.com.

In this powerful episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with Dr. Brian Zheng of Brigham and Women's Hospital and Harvard Medical School to explore a deeply personal yet often overlooked topic: life after a radical cystectomy. Dr. Zheng shares candid insights on the different types of incontinence, how they uniquely affect men and women, and—most importantly—practical tips and treatment options that can dramatically improve quality of life. From behavioral changes and physical therapy to products, medications, and surgical solutions, this episode arms listeners with actionable advice and much-needed hope. If you or a loved one are living with a neobladder, this is an essential listen.

This is a special edition of the Changemaker Podcast which features a series of conversations from the FoodNiche Health Forum held at Harvard Medical School. This session is titled: “Aligning Innovation with Impact: Cross-Sector Collaboration for Sustainable and Healthier Food Systems.”In an era of rising chronic disease and increasing environmental strain, it's clear we need to rethink how our food system works—and who it serves. This panel explores how collaboration across sectors can spark solutions that are not only scalable but truly transformative for both people and the planet.You'll hear from an incredible group of innovators:Marc Oshima, CEO of Babylon Microfarms, shares how decentralized indoor farming is expanding access to fresh, nutrient-rich foods in institutions like schools and hospitals.Alina Zolotareva, Co-founder of VO Health, discusses digital tools designed to personalize and scale preventive nutrition, empowering individuals to take charge of their health through data-driven insights.Dr. Phillip Strandwitz, CEO of Holobiome, unpacks the science of the gut-brain axis and how microbial health could be key to unlocking the next frontier in both mental and metabolic wellness.And Dr. Anabelle Broadbent, a pathogenic microbiologist and Founder at Verde Ops and researcher, brings a systems-level perspective on how to co-create models that promote equity, sustainability, and measurable health outcomes across communities.This conversation is packed with insight, innovation, and inspiration—and is especially timely as we navigate the challenges and opportunities of building a food system that truly supports human and environmental health.

“For complex PTSD, you have to establish a relationship. And only after trust has been established can you do the trauma-focused work.” This week, Thomas sits down with Dr. Judith Lewis Herman, an author and senior lecturer in psychiatry and Harvard Medical School, to explore her groundbreaking work on the psychology and social and cultural aspects of Complex PTSD, or CPTSD. Unlike the better-known diagnosis of PTSD, CPTSD arises from prolonged, repeated trauma that erodes one's sense of self and ability to trust. So, how should we approach healing and therapy for this uniquely challenging diagnosis? Dr. Herman believes there is hope, and it comes from the healing power of relationships…a tough pill to swallow for those whose trauma arose from abusive or coercively controlling relationships. But therein lies the key to healing—a therapeutic bond where the patient's experience is validated, their safety is paramount, and trust is carefully built up through mutuality. But it's not just therapy where healing can occur. Thomas and Dr. Herman discuss the importance of acknowledgment for people who've experienced ongoing trauma and how lifting shame from victims and survivors and transferring it to the perpetrators is an essential shift with powerful healing potential. They also explore social movements, like the women's and civil rights movements, that can lead to helpful reforms and the development of new support systems for trauma survivors.   ✨ Click here to watch the video version of this episode on YouTube:

Soon after Lisa Iezzoni MD was diagnosed with multiple sclerosis during her first year at Harvard Medical School, from which she graduated in 1984, faculty and administrators discouraged her from practicing medicine.  And in her final year they made it impossible for her when the dean's office refused to write a recommendation letter (now called a Medical Student Performance Evaluation).  This week marks the 35th anniversary of the American Disabilities Act which was signed into law on July 26th, 1990. Much has changed since but -- as Dr. Iezzoni, who went on to become an eminent scholar and national policy leader on disability, has documented -- not nearly enough.  She and others have documented wide disparities in the quality of care patients with disabilities still receive, and in 2021 she published the findings of a national study of physician attitudes towards disability that document's persistent stigma and misinformation. Disabled patients were described as a “disruption to clinic flow” and a majority of physicians believed that patients with significant disability inherently have a worse quality of life.  Practices are also ill-equipped to care for them, Dr. Iezzoni, who chaired the U.S. Access Board's advisory committee on accessibility standards for medical equipment observed that “healthcare has been among the most backward environments, in terms of making itself accessible. Movie theaters are accessible, sports stadiums are accessible, transit is accessible. But healthcare facilities—no.” In our conversation with her, we explore why.  How is it that physicians have such difficulty appreciating that disability is simply a part of the human experience? We explore the link between the culture within medical education and training, and the kind of people physicians become.  ------ References: Physicians' Perceptions of People with Disability and Their Health Care US Access Board

In this powerful episode of Research Renaissance, host Deborah Westphal sits down with Dr. Rachel Buckley, Associate Professor of Neurology at Massachusetts General Hospital and Harvard Medical School. Together, they explore a growing body of research that challenges long-standing assumptions about sex differences in Alzheimer's disease.Dr. Buckley shares her unexpected journey from skepticism to advocacy in studying how biological sex and hormonal changes—particularly around menopause—can influence Alzheimer's risk, pathology, and progression. From PET scans to postmortem tissue studies, she unpacks what we now know about tau pathology in women, the role of hormone therapy, and how reproductive history may shape brain health.You'll also hear about:Why women are disproportionately impacted by Alzheimer's—and why it's more than just longevityHow timing of hormone therapy may impact tau buildupSurprising research around pregnancy, caregiving, and even the X chromosomeWhere the research gaps still exist—and how AI might help close themWhy training the next generation of sex-based neuroscientists is essentialWhether you're a caregiver, clinician, researcher, or simply curious about how brain health intersects with gender, this episode offers eye-opening insight and hope for the future.Guest Bio: Dr. Rachel Buckley is an internationally recognized neuroscientist focused on the intersection of sex differences and Alzheimer's disease. She leads groundbreaking research at Massachusetts General Hospital and serves as Chair of the Alzheimer's Association's Sex and Gender Professional Interest Area.Resources & Links: 

Dr. Laura welcomes Kirkland Shave, co-founder of the Mountain Trek health reset retreat, and Dr. Kelly Tremblay, neuroscientist and certified coach, to Where Work Meets Life™to explore the connection between holistic health, burnout prevention, and the mind-body connection. Kelly and Kirk discuss the prevalence of stress and burnout in today's society and our lack of meaningful connection to nature and our own bodies and minds. Dr. Laura investigates these issues from a neurological perspective and a practical wellness approach with both Kelly and Kirk, learning what can be done to reset our healing.Forest bathing, flow trekking and sensory health practices that involve engaging with sound, scent, and visual natural experiences are all part of the conversation. Connecting with our senses and the reality of nature while separating ourselves from screens and demands can dramatically reduce stress and enhance brain function. While Kelly shares neuroscience research linking stress to actual structural brain changes, Kirk offers transformative stories from Mountain Trek, where guests can unplug from digital overload. Dr. Laura highlights the importance of understanding the causes of our burnout and how we can take control to heal our body and mind.“You've probably heard about it's Shinrin-yoku, a Japanese-researched way of being moment to moment, mindful of the sensorial information that's coming through our sense organs into the brain. And you're doing that in nature, and you're in a state of flow… where you're not thinking about other things. You're paying attention to what do I see? Or what do I see in motion in front of me? Or what do I hear out of this ear versus this ear? Or what do I smell as I go by the bark of this tree? Or which direction is the sun landing on my skin? These moment-to-moment awarenesses have been proven to lower the stress hormone cortisol. The Japanese researched this, and the main reason why they did this research is because in the 80s, as the tech industry took off in Japan, people were working 12-hour days already that we're working now, and the work burnout was through the roof.” - Kirkland ShaveAbout Kirkland Shave:Kirkland Shave, founder and president of the world-renowned Mountain Trek program, now offers off-site interactive and eye-opening workshops — grounded in anthropological health science — to help professionals integrate lasting steps in reaching optimal wellness. With an inspiring, practical, and actionable message, Kirkland helps people see their own health through a fresh and practical lens.With half- and full-day interactive health workshops and keynote presentations — designed specifically for a corporate audience — held at your company's headquarters, Kirkland's life-changing interactive presentation can be tailored to meet a number of health issues: Fitness, Nutrition, De-Stressing, Sleep Hygiene, Physical and Digital Detoxification, Habit Formation, Mindfulness.His proven approach increases energy, productivity, and establishes long-lasting health habits. The program incorporates scientific anthropology blended with a distinctly mountain-centric approach to health. With 18 years' experience as president and founder of Mountain Trek's holistic health and vitality program, Kirkland brings more than 40 years of health-focused lifestyle expertise, with experience as a fitness instructor, lead hiking guide, wellness coach, Wilderness Park Manager, yoga instructor and meditation practitioner.Kirkland's off-site workshops for executives and employees have been hosted by leading organizations, such as Google, Young Presidents Organization of Western Canada, Fortis Gas, the CEO Network, European Entrepreneurs Organization, and more. Contact Kirkland Shave and Mountain Trek:Website: MountainTrek.com  https://mountaintrek.com/Instagram: @mountaintrek https://www.instagram.com/mountaintrek/Facebook: @mountaintrek https://www.facebook.com/mountaintrekInstagram: @mountaintrek  https://www.instagram.com/mountaintrekLinkedIn: Mountain-Trek  https://www.linkedin.com/company/mountain-trek/YouTube: YouTube.com/MountainTrek  https://www.youtube.com/mountaintrekKirkland Shave on LinkedIn: https://www.linkedin.com/in/kirkland-shave-66865b29/TripAdvisor: https://www.tripadvisor.com/Hotel_Review-g499116-d223075-Reviews-Mountain_Trek_Fitness_Retreat_Health_Spa-Ainsworth_Hot_Springs_Kootenay_Rockies_British.htmlAbout Dr. Kelly Tremblay, MSc PhD CEC-ACC:Dr. Trembly is committed to making aging better by innovating in the areas of health, tech, and education through leadership, research, and advocacy.She is a consultant, neuroscientist and clinical audiologist who has worked in healthcare, tech, and higher education for 25+ years. As a tenured professor, Dr. Tremblay's NIH-funded research shed light on how we can capitalize on the brain's plasticity to promote perceptual and behavior changes well into our later years. Her work in the areas of communication neuroscience, person-centred care, and digital health technology has been recognized with invitations to serve on many committees at the National Institutes of Health, the American Federation for Aging Research's National Scientific Advisory Council, Mitacs Canada, and the World Health Organization. She leads advocacy initiatives and serves on many boards, including the Hearing Loss Association of America, where she was a Board Trustee and Co-Founder and Chair of the Task Force for Accessible, Inclusive Employment.Because work and health are social determinants of quality of life and healthy aging, Dr. Tremblay also works with leaders in all sectors, as an ICF-certified executive coach, to promote healthy, accessible, multi-generational workplaces where people can flourish. She's certified by the International Coaching Federation and a Fellow of the McLean Institute of Coaching (an affiliate of Harvard Medical School), who loves helping people rewire and inspire!Contact Dr. Kelly Tremblay: Website: DrKellyTremblay.com  https://drkellytremblay.com/LinkedIn: Dr-Kelly_Tremblay  https://www.linkedin.com/in/dr-kelly-tremblay  Resources:Website: MountainTrek.com“Nature and human well-being: The olfactory pathway” Science Advances | May 2024 | Vol 10 Issue 20Parks Canada Health and WellnessShinrin-yoku“The Myth of Normal” by Gabor Mate“When Things Fall Apart” by Pema ChödrönLearn more about Dr. Laura on her website: https://drlaura.liveFor more resources, look into Dr. Laura's organizations: Canada Career CounsellingSynthesis Psychology

Join Adiel and Dr. Martin Moore-Ede, aka "The Light Doctor," in this incredible conversation about the power of light (including the sun) to heal us. After years of sun demonization, while spending most of our days under artificial blue light spectrums, we are now starting to understand the true relationship between our health and light. Not all light is equal, nor is all light beneficial for us at all times of the day. Learn about the true impact of light on our mitochondria and how having a poor light diet contributes to chronic metabolic disease. For over 40 years, Dr. Moore-Ede has been a leading expert on circadian clocks and the health problems including sleep disorders, fatigue, diabetes and cancer caused by light at night. As a professor at Harvard Medical School (1975 – 1998), he led the team that located the suprachiasmatic nucleus, the biological clock in the human brain that controls the timing of sleep and wake, pioneered research on how the human body can safely adapt to working around the clock, and wrote the best-selling book “The Clocks That Time Us”.  

Hal LaCroix discusses with Ivan six things which should be better known. Hal LaCroix lives outside Boston with his wife, Elahna. He has worked as a journalist at newspapers in New England, a reporter and editor at Harvard Medical School, a conservation writer for non-profits and an instructor at Boston University. Here and Beyond is his first novel, which is available at https://www.bloomsbury.com/uk/here-and-beyond-9781526678249/. Senator Charles Sumner. Sumner was a mid-19th century senator with laser focus on one issue: slavery. He had a profound impact on Lincoln, pushing him to expand rights of African Americans after emancipation. Sumner became epic villain in Confederacy, where souvenir canes commemorated the beating were hot items. Hokusai's 36 Views of Mt. Fuji. Fuji is sacred, a symbol of Japan. The 36 mostly long-range views, all around the compass, provide a wraparound view of Japanese life in 1831. Exoplanets. More than 5,000 have been confirmed so far, out of hundreds of billions of planets in the Milky Way galaxy. Until the 1990s no one even knew if there were any planets outside our solar system! Wingspan. This is a board game about birds that my wife and I are a bit obsessed with. Each player has a board with forest, grassland and water habitats. Boston Cream Pie and Boston Cream Donuts. My grandfather used to bring cakes and pies when he visited us on Cape Cod. He'd pull up in his Oldsmobile Cutlass with all these white boxes tied with string from Montilio's bakery. We Need a Global, Unifying Mission. We live on a planet with 8.2 billion people and the vast majority of us just know our neighborhood, our route back and forth to work. But on the spinning ark ship in Here and Beyond, the entire world is visible within the sphere. You look up and see buildings upside down, people upside down. This podcast is powered by ZenCast.fm

Harvard researcher and author Jeffrey Hull reveals the 9 science-backed ways to expand your leadership impact and influence. This changes everything. I'm thrilled to share this game-changing interview with Jeffrey Hull – Harvard Medical School researcher, executive coach, and author of the upcoming book "The Science of Leadership." In this deep-dive conversation, Jeffrey breaks down the psychology behind exceptional leadership and shares actionable strategies you can implement immediately. What You'll Discover:  • The 9 proven ways to expand your impact and influence as a leader • How conscious leadership transforms your effectiveness • The role of ego in leadership (and how to manage it) • Authentic leadership principles that build trust • Advanced relationship-building strategies • The power of empathy in high-performance teams  • Active listening techniques that create breakthrough moments • Science-backed methods for developing your leadership presence KEY TAKEAWAY: Transform your leadership skills into power skills by applying research-proven strategies from one of Harvard's top leadership experts. ABOUT JEFFREY HULL: Jeffrey Hull is a senior lecturer at Harvard Medical School, executive coach, and author of "The Science of Leadership.” His research focuses on the psychology of exceptional leadership and organizational transformation. CONNECT WITH TJ: Subscribe for more success interviews with world-class experts #Leadership #HarvardResearch #ExecutiveCoaching #PersonalDevelopment #Success #Psychology

School is out for the summer, and for most teens, that means unlimited access to doom scrolling and binge watching! And while a little celebratory, post-exam screen time is warranted, the slippery slope of a constant screen in your teen's face presents real threats to their emotional and behavioural development. But how do we get ahead of the algorithms that are designed to keep its users engaged for hours? And how do we set a better example for our teens as we navigate how to mitigate our own over-use? Host Pooja Handa speaks to Dr. Alexandra Gold, Licensed Clinical Psychologist at Mass General Brigham and Faculty at Harvard Medical School, about tangible steps towards a more healthy relationship between your teenager and their devices.We love feedback at The Big Story, as well as suggestions for future episodes. You can find us: Through email at hello@thebigstorypodcast.ca  Or @thebigstoryfpn on Twitter

Show notes (Why We Sleep book summary)⁠ / ⁠Free Full Audiobook⁠ / ⁠PDF & Infographic⁠ / IN THIS EPISODE: Sleep is a complex, essential biological process that significantly impacts physical health, mental function, and emotional regulation, and understanding and prioritizing it can dramatically improve overall human well-being. Read 1 million books in minutes. For free. Visit getstoryshots.com to get started. TOPICS: sleep, Circadian rhythm, health, Dreams, mental health, Neuroscience KEY FIGURES: Pixar, National Institutes of Health, NBA, Atomic Habits, World Health Organization, Centers for Disease Control and Prevention, Harvard Medical School, Why We Sleep, NFL, Matthew Walker, UC Berkeley, Deep Work, Einstein, StoryShots SUMMARY: Matthew Walker's book 'Why We Sleep' reveals a critical insight into the profound importance of sleep for human health, highlighting that most adults in developed nations fail to get the recommended eight hours of sleep. The book explains the complex biological mechanisms behind sleep, including the 24-hour circadian rhythm regulated by the suprachiasmatic nucleus and the buildup of adenosine that creates sleep pressure, demonstrating how these systems interact to govern our sleep-wake cycles. Walker emphasizes that sleep is not a passive state but a critical biological process with distinct stages-NREM and REM sleep-each serving unique functions for physical and mental restoration. During these stages, the body performs essential tasks like tissue repair, memory consolidation, emotional processing, and clearing toxic proteins from the brain. Sleep deprivation has severe consequences, including increased risks of chronic diseases like cancer, heart disease, and diabetes, as well as significant impairments in cognitive function, emotional regulation, and mental health. The book also explores how modern society has created a 'sleep loss epidemic' through factors like artificial lighting, technology, work schedules, and cultural attitudes that devalue sleep. Walker provides practical strategies for improving sleep quality, such as maintaining a consistent sleep schedule, creating a cool and dark sleeping environment, avoiding caffeine and alcohol before bedtime, and establishing a relaxing pre-sleep routine. By understanding and prioritizing sleep, individuals can dramatically improve their overall health, cognitive performance, and emotional well-being. KEY QUOTES: • "Sleeping less than six hours a night is a form of self-inflicted harm that damages every system in your body." - Matthew Walker • "Dreams are not the byproduct of sleep, but rather its purpose, nature's best attempt at emotional first aid." - Matthew Walker • "Our modern world is perfectly designed to disrupt sleep, creating the most sleep deprived era in human history." - Matthew Walker • "The amygdala, your brain's emotional center, becomes 60% more reactive without proper sleep, while the rational prefrontal cortex becomes less active." - Matthew Walker KEY TAKEAWAYS: • Sleep is essential for physical health, with chronic sleep deprivation dramatically increasing risks of serious conditions like cancer, heart disease, and diabetes • Sleep consists of different stages (NREM and REM), each serving unique functions for mental and physical restoration, including memory processing, emotional regulation, and tissue repair • Modern society has created a sleep loss epidemic through artificial lighting, technology, work schedules, and cultural attitudes that devalue sleep • Dreams during REM sleep are crucial for emotional processing, stress reduction, and enhancing creativity by forming unique connections between ideas • Sleep patterns naturally change throughout life stages, with significant variations in sleep needs and rhythms from infancy to old age • Lack of sleep impairs cognitive function, reducing concentration, memory, and decision-making abilities while increasing emotional reactivity... Learn more about your ad choices. Visit megaphone.fm/adchoices

Meet my new doctor, Dr. Sara Szal Gottfried. I am so excited about our new duo! This conversation explores various topics including medical gaslighting, hormonal health, Kayla's labs including genetic testing, nutrition, inflammation, and the impact of environmental toxins. Sara and Kayla emphasize the need for personalized care and proactive health strategies for women, aiming to empower listeners with knowledge and actionable insights.Chapters00:00 Introduction to Women's Health Podcast02:53 Exploring Longevity and Women's Health05:30 The Impact of Medical Gaslighting on Women08:18 Understanding Hormonal Health and Testing11:02 Genetic Testing and Its Role in Women's Health14:02 The Importance of Nutrition and Micronutrients16:44 Addressing Inflammation and Autoimmune Concerns19:28 Toxic Burden and Environmental Exposures22:20 Strategies for Detoxification and Health Optimization25:06 Conclusion and Future TopicsMore About Sara: Dr. Sara Szal Gottfried is a New York Times bestselling author and a board-certified gynecologist known for her work in precision medicine and natural hormone balancing. She graduated from Harvard Medical School and MIT, and completed her residency at the University of California, San Francisco. She has authored several books, including "The Hormone Cure", "The Hormone Reset Diet", "Younger", and "Brain Body Diet". Dr. Gottfried focuses on helping women optimize their health through personalized approaches based on genetics, lifestyle, and environment. Sara Socials + Website IG: https://www.instagram.com/saragottfriedmd/Website: https://www.saragottfriedmd.comHer Podcast on Apple: https://podcasts.apple.com/us/podcast/treated-with-dr-sara-szal/id1799034638Subscribe to Her Podcast on Spotify: https://open.spotify.com/show/1dtiAfWhOpBEtB155MaoJ9?si=1bca702eadf644a5Kayla Socials + WebsiteInstagram:  https://www.instagram.com/kaylabarnes/TikTok:  https://www.tiktok.com/@femalelongevityTwitter: https://x.com/femalelongevityWebsite: https://www.kaylabarnes.comFollow Her Female Protocol: https://www.protocol.kaylabarnes.comBecome a Member of Kayla's Female Longevity Membership: https://kayla-barnes-lentz.circle.so/checkout/become-a-member

In this episode, Dr.Schiffer provides us with  knowledge about how Dual-Brain Psychology offers a deep understanding of one's psychological issues and can become the blueprint to help people work through past traumas that are causing anxiety, depression, PTSD and addiction.Towards the end of the episode, Dr. Schiffer uses me as an example for how to determine which part of the brain is the childlike mind and which is the adult mind.Dr. Fredric Schiffer is a Best Selling Author, Speaker & Psychiatrist who treats Anxiety, Depression and Addiction. Through his groundbreaking work using Dual-Brain Psychology, he has worked with patients dealing with trauma using the concept of two minds competing for dominance - an immature, childlike mind, and a mature, adult mind. When the immature and troubled half of the brain is treated properly, Dual Brain Psychology techniques can successfully curb anxiety, depression, addiction, and PTSD to improve the patient's psychological well-being.Dr. Schiffer's latest book,

On 28 September 2024, join the livestream of a conversation between Dr. Vivek Murthy, MD, US Surgeon General, and Sadhguru where they will explore "Loneliness: In is the Only Way Out". Hosted at the Joseph B. Martin Conference Room, Harvard Medical School, Boston, the session will be moderated by Bala Subramaniam, MD, MPH, Director of Sadhguru Center for a Conscious Planet. Set the context for a joyful, exuberant day with a short, powerful message from Sadhguru. Explore a range of subjects with Sadhguru, discover how every aspect of life can be a stepping stone, and learn to make the most of the potential that a human being embodies.  Conscious Planet: ⁠https://www.consciousplanet.org⁠ Sadhguru App (Download): ⁠https://onelink.to/sadhguru__app⁠ Official Sadhguru Website: ⁠https://isha.sadhguru.org⁠ Sadhguru Exclusive: ⁠https://isha.sadhguru.org/in/en/sadhguru-exclusive⁠ Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode, we dig into two deceptively simple questions: When does someone become a cancer survivor, and should palliative care be in the business of caring for them? Spoiler: It's more complicated than it seems. We've invited two palliative care doctors to talk about survivorship with us: Laura Petrillo, a physician-researcher at Mass General Hospital and Harvard Medical School, and Laura Shoemaker, an outpatient palliative care doctor at the Cleveland Clinic. This episode is a must-listen for those navigating the evolving landscape of cancer care, and asking not just how we treat cancer, but how we support people who are living with it.  If you want some further reading on survivorship, check out some of these articles: A NEJM article titled “Time to Study Metastatic-Cancer Survivorship” A ASCO publication that includes a section on survivorship - Patient-Centered Palliative Care for Patients With Advanced Lung Cancer A webinar on survivorship - Blending Survivorship and Palliative Care (NCI)

  In this Rheumatology Rafael Medina Subspecialty episode, Dr. Ana Valle presents a case of Joint pain and skin rash to Dr. Eli Miloslavsky.  Session facilitator: Rahul Pottabathini Case Discussant: Dr. Eli Miloslavsky is a rheumatologist and Associate Professor of Medicine at the Massachusetts General Hospital and Harvard Medical School. Dr. Eli’s Career has been… Read More »Episode 405- Rafael Medina Subspecialty Episode- Joint pain, rash and dry mouth

Get access to metatrends 10+ years before anyone else - https://qr.diamandis.com/metatrends   David A. Sinclair, A.O., Ph.D., is a tenured Professor of Genetics at Harvard Medical School and a serial biotech entrepreneur.  – Offers for my audience:  Get the first lesson of my executive course for free at https://qr.diamandis.com/futureproof  Test what's going on inside your body at https://qr.diamandis.com/fountainlifepodcast   Reverse the age of my skin using the same cream at https://qr.diamandis.com/oneskinpod    Learn more about my Platinum Longevity Trip: https://qr.diamandis.com/xtrIp  –- FOR DONATION INSTRUCTIONS:  For those interested in contributing to supporting David's work, they can go to this Harvard donation page: https://community.alumni.harvard.edu/give/77182458  For those interested in supporting David Sinclair's work at a higher tier (50K+ USD) and want to qualify for the "Friends of Sinclair Lab Program", send an email to FOSL@diamandis.com  For those looking to donate using digital assets, you are welcome to contribute as much as you want! Reminder, if you contribute $50,000+ in crypto, you are fully eligible for the Friends of Sinclair Lab program as well. Below are wallet addresses for various digital assets (hosted on Coinbase): BTC: 3LVxvVxUkg5qrbbykkCPqsGrUFFt3AyoNY ETH: 0xa04Da1d143B2ffC0C1D53df908E9fc887eb0aBfb USDC (BASE): 0x0282a52f360c5297C955D2449cE1557C7E893937 USDC (ETH): 0x0282a52f360c5297C955D2449cE1557C7E893937 Important Note: These wallet addresses are hosted by Coinbase. Please double-check that you are sending the correct asset on the correct network. Please do not send any other assets. We cannot recover funds sent incorrectly, and we are not responsible for any missent or lost assets. For other meaningful or significant Web3 collaborations (NFTs, longevity DAOs, etc.), contact us at FOSL+Support@diamandis.com. Connect with David:  http://davidasinclair.com  X IG  Podcast Connect with Peter: X Instagram Listen to MOONSHOTS: Apple YouTube – *Recorded on June 6th, 2025 *Views are my own thoughts; not Financial, Medical, or Legal Advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Nicholas Norwitz is a researcher-educator whose mission is to “Make Metabolic Health Mainstream.” He graduated Valedictorian from Dartmouth College, majoring in Cell Biology and Biochemistry. Nick then completed his PhD in Metabolism at the University of Oxford. Next, he went on to Harvard Medical School and completed his MD. Show sponsors: LMNT - Claim your free LMNT Sample Pack with any purchase by using this link Timeline - 10% off your first order of Mitopure by using this link Quicksilver Scientific - 15% off your first order by using the code "ultimatehealth15" at checkout Show notes: https://jessechappus.com/658

Rates of chronic illness, behavioral disorders, and neurodevelopmental challenges are rising rapidly among children, often tied to underlying gut dysfunction, nutrient deficiencies, and environmental triggers such as toxins and ultra-processed foods. Conventional treatments frequently overlook these root causes, relying instead on symptom management or medication. Functional approaches emphasize foundational lifestyle changes—clean nutrition, microbiome support, movement, sleep, and stress reduction—as powerful tools to restore health. Children are especially responsive to these changes, often experiencing rapid and dramatic improvements in behavior, mood, and physical symptoms. With education, testing, and family-centered strategies, parents can take simple, effective steps to help their children thrive. In this episode, I discuss, along with Dr. Elisa Song, Dr. Suzanne Goh, and Dr. Elizabeth Boham why a root-cause approach is just as important for children, as it is for adults. Dr. Elisa Song, MD is a Stanford-, NYU-, UCSF-trained integrative pediatrician, pediatric functional medicine expert, and mom to 2 thriving children - and she is on a mission to revolutionize the future of children's health. Dr. Song is the bestselling author of the Healthy Kids Happy Kids: An Integrative Pediatrician's Guide to Whole Child Resilience. Dr. Song created Healthy Kids Happy Kids as an online holistic pediatric resource to help practitioners and parents bridge the gap between conventional and integrative pediatrics with an evidence-based, pediatrician-backed, mom-approved approach. In her integrative pediatric practice, she's helped 1000s of kids get to the root causes of their health concerns and empowered parents to help their children thrive by integrating conventional pediatrics with functional medicine, homeopathy, acupuncture, herbal medicine, and essential oils. Dr. Song is chair of A4M's pediatric education and has lectured around the world at leading integrative and functional medicine conferences and premier parenting events. She has also been featured in hundreds of top podcasts, print and online media outlets, including the Wellness Mama podcast, BloomTV, Forbes, Healthline, MindBodyGreen, National Geographic, PopSugar, Parents, Motherly, Parade, Verywell Health, and New York Post. Dr. Suzanne Goh, co-founder and chief medical officer at Cortica, is a Rhodes Scholar and graduate of Harvard University, University of Oxford, and Harvard Medical School who has spent decades working with autistic children. Her work as a board-certified pediatric behavioral neurologist, behavioral analyst, neuroscience researcher, and author led her to create the Cortica Care Model, an innovative, whole-child approach that combines optimal medical treatment with the most effective strategies for advancing cognition, communication, and behavior. Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: How to Raise Healthy Kids: A Functional Medicine Approach The Surprising Causes of Autism & Why It's On The Rise Addressing The Root Causes Of Childhood Obesity